T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1176
Eastman Chemical
EMN
$8.37B
| $19.9M | ﹤0.01% |
255,693
+151
| +0.1% | +$11.5K |
|
|
CDK
1177
DELISTED
CDK Global, Inc.
CDK
| $19.8M | ﹤0.01% |
400,564
-1,403
| -0.3% | -$75.1K |
|
1178
Cheesecake Factory
CAKE
$5.63B
| $19.7M | ﹤0.01% |
450,255
-2,158
| -0.5% | -$101K |
|
1179
Saga Communications
SGA
$62.4M
| $19.6M | ﹤0.01% |
628,955
-36,136
| -5% | -$1.11M |
|
1180
AES
AES
$10.5B
| $19.6M | ﹤0.01% |
1,171,096
+10,100
| +0.9% | +$171K |
|
1181
Knight Transportation
KNX
$11.9B
| $19.6M | ﹤0.01% |
596,159
+5,746
| +1% | +$183K |
|
|
NBL
1182
DELISTED
Noble Energy, Inc.
NBL
| $19.5M | ﹤0.01% |
872,708
+1,274
| +0.1% | +$30.2K |
|
|
DISCK
1183
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $19.5M | ﹤0.01% |
686,648
+3,089
| +0.5% | +$83.8K |
|
1184
Phibro Animal Health
PAHC
$1.38B
| $19.5M | ﹤0.01% |
612,464
-372
| -0.1% | -$11.7K |
|
1185
Molson Coors Class B
TAP
$7.85B
| $19.3M | ﹤0.01% |
344,097
-44,709
| -11% | -$2.61M |
|
1186
Aaon
AAON
$7.49B
| $19.3M | ﹤0.01% |
575,499
+148,237
| +35% | +$4.71M |
|
1187
Everest Group
EG
$14B
| $19.1M | ﹤0.01% |
77,407
+119
| +0.2% | +$28.6K |
|
|
IPG
1188
DELISTED
Interpublic Group of Companies
IPG
| $19.1M | ﹤0.01% |
846,907
-15,164
| -2% | -$337K |
|
|
AUTL
1189
Autolus Therapeutics
AUTL
$599M
| $19M | ﹤0.01% |
1,180,396
+645,879
| +121% | +$14.4M |
|
|
CHCT
1190
Community Healthcare Trust
CHCT
$437M
| $18.9M | ﹤0.01% |
480,235
+88,938
| +23% | +$3.31M |
|
|
CMO
1191
DELISTED
Capstead Mortgage Corp.
CMO
| $18.9M | ﹤0.01% |
2,264,815
+1,457,198
| +180% | +$12.2M |
|
1192
Howmet Aerospace
HWM
$113B
| $18.8M | ﹤0.01% |
951,675
-117,515
| -11% | -$1.98M |
|
1193
United Rentals
URI
$70.3B
| $18.6M | ﹤0.01% |
140,564
-585
| -0.4% | -$74.3K |
|
1194
Theravance Biopharma
TBPH
$878M
| $18.6M | ﹤0.01% |
1,139,370
-71,609
| -6% | -$1.45M |
|
|
GSAH.U
1195
DELISTED
GS Acquisition Holdings Corp. Units, each consisting of one share of Class A common stock and one-th
GSAH.U
| $18.6M | ﹤0.01% |
1,768,455
+2,900
| +0.2% | +$30.6K |
|
1196
MGIC Investment
MTG
$6.31B
| $18.6M | ﹤0.01% |
1,412,522
-2,005
| -0.1% | -$27.9K |
|
|
WRK
1197
DELISTED
WestRock Company
WRK
| $18.6M | ﹤0.01% |
508,758
+1,754
| +0.3% | +$64.5K |
|
1198
Stepan Co
SCL
$1.48B
| $18.4M | ﹤0.01% |
199,779
-1,022
| -0.5% | -$91.2K |
|
1199
Jones Lang LaSalle
JLL
$16.8B
| $18.2M | ﹤0.01% |
129,146
+3,209
| +3% | +$456K |
|
|
DRNA
1200
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $18.2M | ﹤0.01% |
1,152,999
+406,960
| +55% | +$5.53M |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.